Karuna Therapeutics Inc
NASDAQ:KRTX
Relative Value
The Relative Value of one KRTX stock under the Base Case scenario is 173.1 USD. Compared to the current market price of 329.83 USD, Karuna Therapeutics Inc is Overvalued by 48%.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Valuation Multiples
Multiples Across Competitors
KRTX Competitors Multiples
Karuna Therapeutics Inc Competitors
Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
---|---|---|---|---|---|---|---|---|
US |
Karuna Therapeutics Inc
NASDAQ:KRTX
|
12.6B USD | 19 203.5 | -29 | -22.9 | -22.8 | ||
US |
Abbvie Inc
NYSE:ABBV
|
284.7B USD | 5.2 | 47.8 | 13.4 | 20.7 | ||
US |
Amgen Inc
NASDAQ:AMGN
|
164.1B USD | 5.6 | 43.6 | 18.4 | 30.4 | ||
US |
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
117.6B USD | 11.5 | 29.3 | 24.6 | 25.7 | ||
US |
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
107.6B USD | 8.2 | 27.9 | 22.5 | 25 | ||
AU |
CSL Ltd
ASX:CSL
|
135.3B AUD | 6.3 | 36.4 | 22 | 27.3 | ||
US |
Gilead Sciences Inc
NASDAQ:GILD
|
79.8B USD | 2.9 | 164.8 | 8.4 | 11.1 | ||
US |
Moderna Inc
NASDAQ:MRNA
|
54.6B USD | 10.6 | -9.1 | -10.2 | -9.1 | ||
US |
Seagen Inc
NASDAQ:SGEN
|
43.1B USD | 18.8 | -57.5 | -61.9 | -55.8 | ||
US |
Biogen Inc
NASDAQ:BIIB
|
32.7B USD | 3.4 | 28 | 14.3 | 17.9 | ||
IE |
Horizon Therapeutics PLC
NASDAQ:HZNP
|
26.6B USD | 7.3 | 60.8 | 27.9 | 47 |